ZA997288B - Azithromycin combination for emesis control in dogs. - Google Patents

Azithromycin combination for emesis control in dogs.

Info

Publication number
ZA997288B
ZA997288B ZA9907288A ZA997288A ZA997288B ZA 997288 B ZA997288 B ZA 997288B ZA 9907288 A ZA9907288 A ZA 9907288A ZA 997288 A ZA997288 A ZA 997288A ZA 997288 B ZA997288 B ZA 997288B
Authority
ZA
South Africa
Prior art keywords
dogs
macrolide antibiotic
antagonist
substance
azithromycin
Prior art date
Application number
ZA9907288A
Other languages
English (en)
Inventor
Richard Todd Darrington
Dennis Michael Godek
Elizabeth Leigh Fraerin Illyes
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA997288B publication Critical patent/ZA997288B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Fodder In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9907288A 1999-01-29 1999-11-24 Azithromycin combination for emesis control in dogs. ZA997288B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11787699P 1999-01-29 1999-01-29

Publications (1)

Publication Number Publication Date
ZA997288B true ZA997288B (en) 2001-05-24

Family

ID=22375307

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9907288A ZA997288B (en) 1999-01-29 1999-11-24 Azithromycin combination for emesis control in dogs.

Country Status (12)

Country Link
US (3) US20020016301A1 (de)
EP (1) EP1027892B1 (de)
JP (1) JP2000219640A (de)
KR (1) KR20000052444A (de)
AT (1) ATE302013T1 (de)
AU (1) AU6065799A (de)
CA (1) CA2290771A1 (de)
DE (1) DE69926722D1 (de)
HU (1) HUP9904393A2 (de)
IL (1) IL133077A0 (de)
NZ (1) NZ501211A (de)
ZA (1) ZA997288B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030011797A (ko) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
GB0315671D0 (en) * 2003-07-04 2003-08-13 Chelsea And Westminster Nhs Tr Improvements in or relating to organic compounds
JP2009539970A (ja) 2006-06-12 2009-11-19 ラモット アット テル−アビブ ユニバーシティー リミテッド 癌の治療方法
JP2012502915A (ja) 2008-09-15 2012-02-02 バイオビスタ インコーポレイテッド てんかんを治療する組成物及び方法
WO2012082992A1 (en) * 2010-12-15 2012-06-21 Biovista, Inc. Compositions and methods for cancer treatment
US20150018362A1 (en) 2012-02-27 2015-01-15 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
KR20230155155A (ko) * 2022-05-03 2023-11-10 녹십자수의약품 주식회사 마크로라이드 계열 항생제를 유효성분으로 포함하는 개과 동물의 호흡기 질환의 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63107994A (ja) * 1986-05-02 1988-05-12 Taisho Pharmaceut Co Ltd エリスロマイシン誘導体
ATE195867T1 (de) * 1991-09-20 2000-09-15 Glaxo Group Ltd Neue medizinische indikation für tachykinin- antagonisten
MX9308001A (es) * 1992-12-21 1994-08-31 Lilly Co Eli Premezcla para piensos de animales que contiene tilosina y procedimiento para su obtencion.
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
FR2740335B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, de lithium, d'etain, de zinc, de manganese ou d'yttrium comme antagoniste de substance p
CA2189501A1 (en) * 1995-11-06 1997-05-07 Harry R. Howard Nk-1 receptor antagonists for the treatment of cancer
US5958888A (en) * 1996-07-02 1999-09-28 Merial, Inc. Water miscible macrolide solutions

Also Published As

Publication number Publication date
EP1027892B1 (de) 2005-08-17
US20030018049A1 (en) 2003-01-23
IL133077A0 (en) 2001-03-19
JP2000219640A (ja) 2000-08-08
US20020016301A1 (en) 2002-02-07
HUP9904393A2 (en) 2002-09-28
EP1027892A2 (de) 2000-08-16
NZ501211A (en) 2001-10-26
KR20000052444A (ko) 2000-08-25
US20040063649A1 (en) 2004-04-01
AU6065799A (en) 2000-08-03
CA2290771A1 (en) 2000-07-29
EP1027892A3 (de) 2002-06-19
HU9904393D0 (en) 2000-01-28
DE69926722D1 (de) 2005-09-22
ATE302013T1 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
PT806941E (pt) Composicoes anti-bacterianas liposomicas de rigidez baixa
NZ335825A (en) Use of azithromycin for treating atherosclerosis
ATE161265T1 (de) Derivate von 16-gliedrigen antibiotischen macroliden
HUP0300585A3 (en) Process for the use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals
IL133077A0 (en) Azithromycin combination for emesis control in dogs
PH25096A (en) Opthalmic use of napththyridine antibiotic
NO20001439L (no) 3'-N-modifiserte 6-O-substituerte erytromycin ketolid- derivater med antibakteriell aktivitet
EP0708770A1 (de) Amid-derivate von 16-gliedrige heterocyclen als antibiotische macrolide
GR3036873T3 (en) Dialkyltiacumicin compounds
IE831920L (en) 2,4-diamino-5-piperazinyl pyrimidines
IL101394A0 (en) New compounds,named"leustroducins",their preparation and their therapeutic use
MD1788G2 (ro) Derivaţi de 9-O-oximă ai Eritromicinei A, compoziţie farmaceutică pe baza lor şi metodă de tratament al bolilor infecţioase
HU9403502D0 (en) 9 a-n-(n`-carbamoyl) and 9 a-n-(n`-thiocarbamoyl) derivatives 9-deoxo-9a-aza-9a-homoerythro-mycin a
WO1990006307A3 (en) Antibacterial quinolone compounds
EP1227721A4 (de) Neue substituierte bernsteinsäure metall-beta-lactamase-inhibitoren und ihre verwendung zur behandlung von bakteriellen infektionen
AU3515193A (en) Antimicrobial carbapenem derivatives, their preparation and their therapeutic use
GR3003852T3 (de)
EP0416327A3 (en) Chemical derivatives of antibiotics ll-e19020 alpha and beta
WO2000078772A3 (en) Antibiotic agents
IN164553B (de)
MX9803694A (es) Derivados de 3-desoxi-3-desclandinosa de eritromicinas a y b.
UA22243A (uk) Спосіб лікуваhhя локальhих гhійhо-запальhих захворюваhь
IT1313628B1 (it) Uso di compositi di fluorochinolone contro batteri dell'apparatorespiratorio